[O7] Oral Session 7　消化器2（下部消化管-大腸癌1）
【E】

[O7-3] Pembrolizumab vs chemotherapy in MSI-H / dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis Asia subgroup

^○吉野 孝之¹, André Thierry², Shiu Kai-Keen³, Won Kim Tae⁴, Jensen Benny Vittrup⁵, Jensen Lars Henrik⁶, Punt Cornelius J. A.⁷, Smith Denis⁸, Garcia-Carbonero Rocio⁹, Gibbs Peter¹⁰, Dung T. Le¹¹, Adachi Noriaki¹², Fogelman David¹³, Marinello Patricia¹³, Diaz Jr. Luis A.¹⁴ (1.国立がん研究センター東病院, 2.Hopital Saint-Antoine, Paris, France, 3.University College Hospital, NHS Foundation Trust, London, UK, 4.Asan Medical Center, Seoul, South Korea, 5.Herlev and Gentofte Hospital, Herlev, Denmark, 6.University Hospital of Southern Denmark, Vejle, Denmark, 7.Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands, 8.Hopital Haut Leveque, Pessac, France, 9.Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, Spain, 10.Western Hospital, Footscray, VIC, Australia, 11.Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA, 12.MSD KK, Tokyo, Japan, 13.Merck & Co., Inc., Kenilworth, NJ, USA, 14.Memorial Sloan Kettering Cancer Center, New York, NY, USA)